Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 13, 2026
Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: February 11, 2026
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: August 05, 2025
Microsurgical Trapping, Flow Diversion and Early Chemotherapy for a Ruptured Neoplastic Middle Cerebral Artery Aneurysm Secondary to Choriocarcinoma.
Journal: Neurosurgery practice
Published: June 05, 2025
The Impact of the COVID-19 Pandemic on Medical-Legal Partnership Services and Cases.
Journal: Journal of public health management and practice : JPHMP
Published: January 08, 2025
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 20, 2024
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: October 16, 2024
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.
Journal: Molecular carcinogenesis
Published: April 23, 2024
Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 19, 2024
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: December 11, 2023
Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer.
Journal: Oncogene
Published: August 20, 2021
The four and a half LIM domains 2 (FHL2) regulates ovarian granulosa cell tumor progression via controlling AKT1 transcription.
Journal: Cell death & disease
Published: February 19, 2016
Last Updated: 09/26/2026